Background: Myofascial pain syndrome (MPS) in the shoulder is among the most prevalent pain problems in the middle-aged population worldwide. Evidence suggests that peripheral and central sensitization may play an important role in the development and maintenance of shoulder MPS. Given previous research supporting the potential efficacy of anodal transcranial direct current stimulation (tDCS) for modulating pain-related brain activity in individuals with refractory central pain, we hypothesized that anodal tDCS when applied over the primary motor cortex (M1) combined with standard treatment will be more effective for reducing pain in patients with MPS than standard treatment alone.
M yofascial pain syndrome (MPS) has been defined as pain referred from active myofascial trigger points (MTrPs) with associated dysfunction. 1 The pathophysiology of MTrPs is thought to be related to mechanical overload or mechanical trauma leading to increase fiber tension, which then result in taut bands, increased muscle tension, and restricted range of motion. 2 In the absence of perpetuating factors, such as ongoing microtrauma and macrotrauma from overexertion, poor body mechanics, and psychological stress, among others, 3 acute MTrPs usually resolve. 4 However, in the presence of perpetuating factors, or if inadequately managed, MTrPs are thought to persist and may propagate as secondary and satellite MTrPs, leading to progressively more severe and widespread chronic MPS. 1, [5] [6] [7] However, the role that MTrPs play in the development and maintenance of MPS has not been confirmed, and a number of additional factors have been proposed as playing a causal role in MPS, including those related to peripheral sensitization, 8 ischemic muscle spasm, 9 neuromuscular dysfunction, 10 motor end-plate hyperactivity, 11 and central sensitization. 12, 13 Many of these factors have also been hypothesized as mechanisms of fibromyalgia. 14 Moreover, the various models of MPS are not necessarily mutually exclusive; it is possible-even likely-that MPS may be associated with or results from more than one of these purposed mechanisms. 13 The standard treatment of chronic MPS usually includes muscle stretching and physical therapy. 1 However, no treatment has been identified that successfully eliminated pain and disability in all patients with MPS. 1, [5] [6] [7] Therefore, there is a need to develop and examine the efficacy of additional treatments for this disorder.
Transcranial direct current stimulation (tDCS) is a painless and safe method for focal brain stimulation. 15 tDCS is based on decade-old observations that neuronal firing can be modulated by low-amplitude electrical direct current. 16 Although the electrical current used in tDCS is low, it is large enough to decrease the threshold needed to generate an increase in action potentials in the neurons immediately below the anodal (positive) electrode. Thus, it is thought to modulate cortical excitability by altering cell membrane potential. Although the precise mechanisms that underlie tDCS are not yet completely understood, the overall effect on the human cortex is reliable, such that anodal tDCS facilitates cortical activity and cathodal tDCS depresses cortical activity. 17 Recently, a number of studies have suggested that motor cortex stimulation with tDCS can decrease the intensity of chronic pain, at least for some pain conditions. For example, Fregni et al 18 randomly assigned individuals with pain associated with a spinal cord lesion to receive sham or active anodal tDCS over the left or right M1 (2 mA, 20 min) for 5 consecutive days. They found that significantly greater pain intensity reductions in those who received active tDCS than in those who received sham tDCS. Maximal pain relief in this study was found at the end of 1 week of stimulation and remained significant 3 weeks later. A second study from this group showed that anodal tDCS over M1 also produced decreases in pain intensity in patients with fibromyalgia that were maintained for up to 3 weeks. 19 Finally, Silva et al 20 published a case report describing how anodal tDCS over M1 may induce analgesic effects in cancer pain. The patient in this study had severe pain for several months and responded well to active, but not sham, anodal tDCS over M1. Other research suggests the possibility of anodal tDCS for treatment phantom limb pain 21 and migraine headache. 22 However, research findings do not universally support the efficacy of tDCS for reducing chronic pain. 23 As a group, these findings provide preliminary support for the possibility that anodal tDCS applied over M1 may be effective for treating some-but not all-types of chronic pain.
As mentioned previously, no research has yet examined the effects of tDCS for chronic MPS. However, given that chronic MPS may share some pathophysiology with other chronic pain conditions that could be amendable to neuromodulatory treatments-specifically, central sensitization 12,13 -it is reasonable to examine the potential effects of tDCS on MPS. We hypothesized that 5 days of tDCS stimulation would result in significantly more pretreatment to posttreatment decreases in pain intensity than 5 days of sham (placebo) tDCS stimulation, and that the differences in pain intensity would maintain for at least 4 weeks posttreatment. In addition to testing the primary hypothesis, and consistent with the call to assess the effects of pain treatments on more than just pain intensity, 24 we also explored the effects of tDCS, relative to a sham condition, on measures of passive range of motion (PROM) in the affected shoulder, analgesic medication use, and physical functioning.
METHODS AND MATERIALS

Participant Recruitment and Informed Consent
Study participants were recruited through advertisement at the Physical Therapy Clinic, Faculty of Associated Medical Science, Khon Kaen University, Khon Kaen, Thailand. The study procedures were described to any eligible patient who expressed an interest in participating in the study by clinic physicians. MPS diagnosis was confirmed by a physician. Study inclusion criteria included: (1) a diagnosis of chronic myofascial pain in the shoulder; (2) stable doses of analgesics for at least 3 months before study participation; (3) an average pain intensity over the past week score of Z4 on a 0 to 10 numerical rating scale (NRS); and (4) age between 18 and 65 years. The criteria used for a diagnosis of chronic myofascial pain were that described by Yunus, 25 and included: (1) pain of at least 3 months' duration; and (2) spontaneous upper back pain that had at least 1 trigger point in the serratus posterior superior, rhomboid, levator scapulae, supraspinatus, trapezius, infraspinatus, subscapularis, teres major, and teres minor muscle. Trigger points were defined as the presence of tender points within palpable taut bands of muscle in the areas that the patient identified as painful. Study exclusion criteria included: (1) previous diagnosis of shoulder pathology other than MPS that could contribute to pain, including subluxation, instability, fractures, frozen shoulder, infection, inflammation or degenerative changes such as osteoarthritis, bursitis, and tendinitis; (2) a diagnosis of neurological disease such as Alzheimer or Parkinson; (3) severe psychiatric conditions or symptoms such as schizophrenia, major depression, or mania; (4) current pregnancy or lactation; (5) the presence of a skull defect; and (6) current use of herbal remedies and other alternative therapies such as massage for pain.
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Khon Kaen University (identifier number: HE 542339). Written informed consent was obtained from all participants.
Experimental Design
The current study was a randomized double-blind controlled trial conducted over a total of 9 weeks consisting of (1) 4 weeks of baseline; (2) 5 days of treatment; and (3) 4 weeks of follow-up. Just before the treatment phase, study participants were randomized in a 1:1 ratio in blocks of 4 randomizations to receive either (1) standard care plus active tDCS stimulation; or (2) standard care plus sham tDCS stimulation for 1 week. Participants were asked to continue their routine analgesic medication regimen throughout the duration of the 9-week trial.
Active and Sham tDCS
tDCS was applied using 0.9% NaCl-soaked pair of surface sponge electrodes (35 cm 2 ) and delivered through battery-driven power supply. The constant current stimulator had a maximum output of 10 mA (Model 1224-B; Soterixmedical, New York, NY). The stimulation site over the M1, contralateral to the most painful side, located based on the international electroencephalography 10/20 electrode placement system. The cathode (reference) electrode was placed over the supraorbital area contralateral to the anode electrode.
The tDCS device was designed to allow for masked (sham) stimulation. Specifically, the control switch was in front of the instrument, which was covered by an opaque adhesive during stimulation. The power indicator was on the front of the machine, which lit up during the time of stimulation both in active and sham stimulations. However, in sham stimulation, the current was discontinued after 30 seconds, whereas the power indicator remained on. 26 
Standard Care
All study participants were given the standard treatment for MPS provided in our clinical setting. 1 Specifically, after the trigger points were identified, patients were taught active stretching exercises. We followed Travell and Simons' procedure 1 for this exercise program: slow-sustained stretching of the group of muscles throughout the available ROM. Stretching stops at the point of pain, and then moves slowly and gently just a little further with the goal of decreasing muscle tightness. Patients were asked to perform daily stretching activities of both shoulders throughout the study period and received treatment at the hospital. Treatment also included ultrasound therapy for 5 to 10 minutes followed by the application of hot packs over the affected part for 20 minutes 3 times/week for 2 weeks. All participants also received the instructions to assume and maintain good posture. 27 
Measures
Four outcome domains were assessed in this study: pain intensity, PROM, analgesic medication use, and quality of life.
Average Pain Intensity
Pain intensity was the primary outcome variable, and was assessed by using a 0 to 10 NRS with the endpoints "No pain" and "The most possible pain." For the baseline (pretreatment) assessment, participants were asked to provide daily ratings of average pain in the past 24 hours every day for 28 days during the baseline period on a daily diary. These 28 ratings were averaged into a single composite score of baseline average pain intensity. Immediately after treatment, participants were asked to rate their current pain on the same 0 to 10 scale. Finally, daily 24-hour recall ratings were administered for 4 weeks following treatment. 1-, 2-, 3-, and 4-week composite scores of average pain were computed as an average of the daily ratings for each epoch (ie, the 1-week followup average pain intensity score = average of 7 daily ratings during the first week after treatment). NRSs (0 to 10) have a great deal of evidence supporting their reliability and validity as measures of pain intensity, [28] [29] [30] and have been recommended as an outcome measure by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). 28 
PROM
Shoulder PROM refers to the number of degrees of motion present in a shoulder joint. PROM of shoulder flexion/extension, abduction/adduction, internal/external rotation were measured following the procedures described by Norkin and White, 31 using a goniometer, by an experienced physical therapist (T.J.). PROM was assessed on the affected side at 4 weeks before treatment and again at posttreatment and 1-, 2-, 3-, and 4-week follow-up.
Analgesic Medication Use
Analgesic medication use was recorded on a medication diary as the total number of tablets of analgesics taken each week during the 4-week baseline period, the 1 week of treatment, and weekly at each follow-up assessment. All study participants were prescribed prn acetaminophen up to 1000 mg every 6 hours for mild pain, and either prn ibuprofen 400 mg one tablet every 8 hours or prn diclofenac 25 mg one tablet every 12 hours, for moderate pain. These prescriptions were viewed as a component of standard treatment. 32 Participants were allowed to alter the amount of analgesic medication use as needed throughout the study, but were not prescribed any analgesics other than acetaminophen, ibuprofen, or diclofenac, and change in type or dose of analgesics used did not occur.
Thus, the number of tablets taken represents a consistent measure of analgesic use over time for each participant.
Physical Functioning
Physical functioning was assessed using the 7 physical functioning items from the brief World Health Organization quality of life (WHOQOL), which has been translated and validated into Thai (WHOQOL-brief-Thai). 33 With the WHOQOL, raw scores are transformed into a 0 to 100 metric. The items were administered just before treatment and again at 4-week follow-up.
Data Analysis
We first computed means and SDs of the demographic and outcome variables for descriptive purposes. Next, we compared the 2 treatment conditions (active tDCS vs. sham tDCS) on all baseline outcome measures to ensure baseline equivalence using t tests. Because dropouts could indicate either treatment failure or lack of improvement leading patients to discontinue participation, we used intent-to-treat analyses, using last observation carried forward for imputing the endpoint scores for tests of the primary and exploratory hypotheses. Results are presented as means and SEM. Both the primary (related to pain intensity) and exploratory (related to PROM, analgesic medication use, and physical functioning) hypotheses were tested using repeated-measures analysis of variance (ANOVA) followed by least significant difference to help understand any significant effects found. To describe the clinical meaningfulness of any change in pain, we computed the rates of participants in each condition who reported 30% and 50% reductions in pain intensity from pretreatment to posttreatment and from pretreatment to 4-week followup. 29 For all analyses, P-values of <0.05 were considered statistically significant. Analyses were completed using Stata software, version 10.0 (StataCorp, College Station, TX).
RESULTS
A total of 35 patients were recruited for participation in this study between December 2009 and April 2013. Four patients did not meet the inclusion criteria. Participant flow is shown in the Consort diagram in Figure 1 . One of the participants in the sham group dropped out at week 4 for a personal reason unrelated to the study. Table 1 presents the descriptive variables for study participants.
Pain Intensity
Repeated-measures ANOVA with group as a betweensubjects factor and time as a within-subjects factor revealed a significant main effect for group (F 1,29 = 6.479; P = 0.016), time (F 5,29 = 214.93; P < 0.001), and a significant GroupÂ Time interaction (F 5,29 = 4.946; P < 0.001). Post hoc analyses showed that participants in the active tDCS condition reported significantly lower pain intensity than participants in the sham tDCS condition at posttreatment (P < 0.001), and at 1-week follow-up (P = 0.002). However, no significant differences emerged between the 2 treatment conditions at 2-, 3-, and 4-week follow-up (Fig. 2 ).
Meaningfulness of Pain Reduction
At posttreatment, none of the participants in either group reported a Z50% pretreatment to posttreatment reduction in pain. However, 12 (75%) of the participants in the tDCS group and none (0%) of the participants in the sham group reported a 30% or more reduction in pain intensity. This rate difference was statistically significant (w 2 2 = 18.35, P < 0.001). At the 4-week follow-up point, all participants in both treatment conditions reported a Z30% reduction in pain intensity, relative to pretreatment levels. However, at 4 weeks, 15 (94%) of the participants in the tDCS group reported a Z50% reduction in average pain intensity, whereas only 7 (47%) of the sham group participants reported these levels of pain reduction. This difference in responder rates was also statistically significant (w 2 2 = 8.33, P = 0.004).
PROM
The repeated-measures ANOVA using shoulder adduction PROM as a dependent variable revealed significant main effects for group (F 1,29 = 5.11; P = 0.031) and time (F 5, 29 =16.61; P < 0.001), and a significant GroupÂTime interaction (F 5,29 = 6.72; P < 0.001). Post hoc analysis showed that the shoulder adduction PROM was significantly greater in the tDCS group, relative to the sham tDCS group, at 1 week (P = 0.047). However, there was no statistically significant difference in shoulder adduction PROM at any other time point. In addition, we found no statistically significant differences between the treatment conditions in PROM of shoulder flexion, shoulder extension, shoulder abduction, shoulder internal rotation, and shoulder external rotation. However, a review of the PROM scores across time (Fig. 3 ) indicated a trend of greater PROM across all domains for the tDCS group than the sham tDCS group.
Analgesic Medication Use
The majority of our patients (25/31) received acetaminophen for pain during the study period. We therefore compared the use of acetaminophen between treatment groups. Repeated-measures ANOVA with group as a between-subjects factor and time as a within-subjects factor revealed a significant main effect on number of acetaminophen tablets taken for group (F 1,23 = 65.80; P < 0.001), time (F 4,23 = 11.75; P < 0.001), and a significant GroupÂTime interaction (F 4,23 = 5.32; P = 0.001). Post hoc analyses showed that participants in the active tDCS condition reported taking significantly fewer acetaminophen tablets than participants in the sham tDCS condition at 1-week (P < 0.001) and 2-week follow-up (P = 0.019). However, no significant differences in acetaminophen use were found between the 2 treatment conditions at 3-and 4-week followup ( Fig. 4 ).
Physical Functioning
The repeated-measures ANOVA using the physical domain of WHOQOL-brief-Thai as the dependent variable revealed significant main effects for group (F 1,29 = 820.78; P < 0.001) and time (F 1,29 = 153.15; P < 0.001), but no significant GroupÂTime interaction (F 1,29 = 0.787; P = 0.382). Despite the significant group main effect, post hoc analyses revealed no statistical difference between groups at either time point (P = 0.180) ( Fig. 5 ).
Adverse Events
Two patients (13%) in active group developed a transient erythematous rash with no pruritus or pain under the reference electrode (anode), which resolved within 1 hour. No other adverse events in participants in the active or sham groups were reported by the participants or observed by the investigators. 
DISCUSSION
To the best of our knowledge, this is the first randomized control trial examining the efficacy of anodal tDCS when combined with standard care in the treatment of patients with chronic MPS. The primary outcome revealed a significantly greater pretreatment to posttreatment decrease in pain intensity that was maintained for 1 week among participants in the active tDCS condition, relative to those in the sham tDCS condition. We also found statistically significant between-group differences in the secondary outcome variables emerged for shoulder adduction PROM at 1-week posttreatment. These treatment effects on shoulder adduction PROM did not maintain at the 2-week through 4-week assessments, although for the pattern of findings for this many of the other PROM measures were suggestive of better outcomes for the active tDCS group, relative to the sham tDCS group. In addition, we found significant decreases in the primary analgesic (acetaminophen) use from during the first 2 weeks after treatment in active tDCS group, relative to the sham tDCS group. No significant between-group differences emerged for physical functioning.
Because this is the first study evaluating anodal tDCS in patients with chronic MPS, a comparison with previous results of tDCS in this patient population is not possible. However, a number of previous studies have shown some promising beneficial effects of tDCS in patients with other chronic pain conditions. When benefits were found in those other studies, the analgesic effect occurred immediately after 5 days of anodal tDCS stimulation. 18, 19, [34] [35] [36] [37] [38] [39] Our results are consistent with these findings, as we also found statistically significant reductions in pain intensity immediately after 5 days of stimulation that were maintained for 1 week. However, the significant between-group differences in pain intensity disappeared by the second week of follow-up. There are at least 3 possible reasons for the relatively short duration of effects. First, assuming that the treatment dose was ideal, it is possible that the longest duration of benefit that patients with shoulder MPS can expect with tDCS (without booster treatments) is 1 to 2 weeks. Second, the limited duration of effects might have occurred because we did not provide the best or most effective dose (frequency of treatment, duration of treatment sessions, current intensity) of tDCS. Further research is needed to determine whether changes in treatment frequency, treatment duration, or current intensity affect the magnitude or duration of treatment benefits. Third, it is possible (as discussed in more detail below) that some or all of the benefits found in this trial could have been because of placebo effects. Although previous research has found effects of anodal tDCS on pain intensity 18, 19, [34] [35] [36] [37] [38] [39] and brain metabolites, [40] [41] [42] [43] either or both of these effects could theoretically also occur with placebo treatment.
Statistically significant improvement does not necessarily translate to clinically meaningful improvements in pain. To understand the clinical meaningfulness of the improvements observed in both treatment conditions fully, we computed the rates of 30% and 50% or more reduction in pain from pretreatment to both posttreatment and 4week follow-up. 29 We found that participants in the tDCS reported meaningful reductions in pain more often at both posttreatment and at 4-week follow-up than participants in the sham condition. This provides further support for the efficacy of tDCS, and that its benefits-at least in the short term-are clinically meaningful.
We also found more rapid improvements in PROM at 1 week after treatment and significantly lower analgesic used in participants who received active treatment than in participants in the sham tDCS condition at 1-and 2-week follow-up. These findings are consistent with the findings regarding pain intensity, supporting the short-term benefits of tDCS for MPS. However, no significant between-group differences emerged for physical functioning; participants in both treatment conditions reported significant (and similar) pretreatment to posttreatment improvements in physical functioning after treatment. The most likely explanation for the disconnect found between change in pain and change in functioning is the fact that pain intensity and physical functioning are different domains and can influence each in complicated ways. Pain is one of many factors that can affect functioning. To have an impact on functioning, a treatment needs to either (1) effectively target functioning directly (such as the physical therapy treatment that both treatment groups in our study received); or (2) have a large enough impact on pain intensity for it to subsequently influence functioning. We speculate that although the effects of tDCS on pain intensity were statistically Active tDCS with standard treatment
Physical Functioning
Sham tDCS with standard treatment Baseline Week4 significant overall and clinically meaningful for many, the between-group differences in pain intensity that occurred were still not large enough to result in between-group differences in physical functioning. The mechanisms of tDCS's effects on pain intensity have not been confirmed. Some investigators have hypothesized that some individuals with chronic pain may have deficits in intracortical inhibition. 36 Because tDCS induces a weak, constant electric current that alters resting membrane potential, it increases overall firing activity in the cortical areas immediately below the anode electrode. 44 Thus, it is possible that tDCS may facilitate greater activity in brain areas involved in the inhibition of signals. Consistent with this possibility, neuroimaging research has shown that stimulation of the motor cortex with epidural electrodes changes activity in thalamic and subthalamic nuclei. 45 It is possible that thalamic nuclei activation, which occurs after motor cortex stimulation, could lead to changes in activity in other pain-related structures, such as the anterior cingulate, and the periaqueductal gray. 46 It is also possible that active tDCS increases the synaptic transmission modulation by the NMDA receptors. 47 In contrast, a recent study suggests that the sham tDCS procedure commonly used in tDCS researchincluding the present study-might not be truly blind to patient participants. 23 Thus, it remains possible that the beneficial effects of active tDCS relative to sham tDCS may be partly because of placebo effects. Unfortunately, we did not test the efficacy of the blinding procedure in this study. Future research should test for the success of any blinding procedure used and develop a better (ie, more effectively blinding) sham tDCS procedure if needed.
To the extent that the benefits obtained in this study with the tDCS plus standard care treatment are specific and not due to placebo or expectancy effects, and given the increase in shoulder adduction PROM that we observed, it is possible that in individuals with MPS, anodal tDCS might facilitate a relaxation of the MTrP taut band that could then respond more to stretching exercises used in standard MPS treatment. 48 Consistent with this possibility, our results are similar to those reported for the application of high-power ultrasound 49 or TENS plus stretching 50 over the MTrP within the upper trapezius, where an increase in cervical lateral flexion has been observed. In short, our findings suggest that anodal tDCS could be combined with standard care to help make standard care more comfortable for some patients, at least during the first 2 weeks of standard care. It may be particularly useful in patients for whom other options for pain relief are limited. 51 If improvements in range of motion contribute to an overall benefit for patients with MPS, our findings regarding the potential of tDCS for enhancing ROM warrant further exploration and testing.
An important limitation of the current study is the relatively small sample size. Thus, it may have been underpowered to detect the effects on PROM that appeared to emerge across a number of the PROM variables. Additional examination of tDCS's impact on PROM in individuals with MPS, ideally in studies with larger sample sizes, is warranted. Second, we did not image brain activity before and after treatment, and thus we are not able to provide findings related to possible neurophysiological mechanisms of tDCS's benefits.
Third, although we used standard procedures (ie, the international 10 to 20 system) for electrode placement, we did not confirm that the electrode was directly over the motor cortex, using for example transcranial magnetic stimulation to locate motor responses. 52, 53 Moreover, given the size of the electrodes (35 cm 2 ), tDCS procedures likely result in more generalized (hemicortical) stimulation than very specific stimulation. Thus, we cannot confirm that the M1 cortex (and only the M1 cortex) was stimulated in this study, and therefore whether M1 stimulation (vs. other areas) explain or underlie the benefits found. Finally, as we have already mentioned, recent research (not available at the time that the current study was designed and conducted) suggests the possibility that the sham tDCS procedure used may not be as effective as a truly blind sham procedure. Future studies should examine the efficacy of the blinding procedure used in study participants and use an alternative sham procedure, if needed to ensure successful blinding.
Nevertheless, despite the study's limitations, to the best of our knowledge this is the first study to demonstrate that anodal tDCS over the motor cortex when combined with standard treatment may have immediate beneficial effects on pain intensity, PROM, and analgesic medication used in individuals with chronic shoulder pain. Further research is needed to examine these effects in larger samples of patients and to more closely examine the potential mechanisms of treatment using neuroimaging techniques.
